Research projects funded in 2024
It is safe to say that research provides better quality of life and will lead, one day, inevitably to cures. This is why the Canadian Hemophilia Society (CHS) is promoting, funding, facilitating or conducting fundamental clinical and quality-of-life research to improve health and quality of life and ultimately find cures.
In 2024, the CHS is funding nine research projects through four different research programs:
- The CHS Dream of a Cure Research Program
- The CHS – Pfizer Care until Cure Research Program
- The CHS – Novo Nordisk Canada Psychosocial Research Program
- The CHS – Bayer – ADVANCE Canada Research Program
Supporting research towards improving the quality of life for people with inherited bleeding disorders and finding a cure have been goals of the Canadian Hemophilia Society (CHS) since it was founded in 1953. Since 1990, through funds provided by the Hemophilia Research Million Dollar Club and the CHS, the CHS provides basic scientific research grants and studentships aimed at developing treatments for inherited bleeding disorders and finding a cure.
THE FOLLOWING PROJECTS ARE BEING FUNDED IN 2024:
The CHS – Pfizer Care Until Cure Research Program established in the year 2000 in collaboration with Wyeth Canada, now Pfizer, allows Canadian investigators to conduct research on medical and psychosocial aspects of bleeding disorders, including outcome evaluation. Grants are awarded for clinical research in fields relevant to improving the quality of life for persons with hemophilia, persons with von Willebrand disease or other inherited bleeding disorders, persons with related conditions such as HIV or hepatitis C, and carriers of an inherited
THE FOLLOWING PROJECTS ARE BEING FUNDED IN 2024:
The CHS – Novo Nordisk Canada Psychosocial Research Program was created to engage professionals/graduate students from the allied health disciplines (ie. nursing, physiotherapy and social work) in research activities addressed to understanding the psychosocial impact of hemophilia and other inherited bleeding disorders and to improve the quality of life of persons and families whose lives are affected by these disorders.
THE FOLLOWING PROJECT IS BEING FUNDED IN 2024:
The CHS – Bayer – ADVANCE Canada Research Program was created to engage Canadian hemophilia treaters in activities to identify and research key issues in the ageing hemophilia population. Its goal is to support research that will help inform how management and treatment should best be adapted for people ageing with hemophilia. In order to optimize management of age-related co-morbidities, ADVANCE Canada fosters patient-centred research, and disseminates scientific information to assist physicians.
THE FOLLOWING PROJECT IS BEING FUNDED IN 2024:
Detailed descriptions of all the funded research projects in 2024 are available at www.hemophilia.ca/research.